Case study: Haemophilia Digital Advisory Board
19th April 2024 by Priya Bhogal
Current haemophilia treatments are subject
to frequent intravenous infusions. Gene therapy introduces a new option for patients.
If successful, it only involves a one-time infusion treatment.
The ask
Our client needed to gain a better understanding around the
current UK readiness for gene therapy as a treatment for haemophilia. Our
collaboration would involve patient and clinician perspectives, patient
information requirements, logistics and governance, practical implications, and
phase 3 trial data and data gaps.
The solution
We ran a 12-month asynchronous
advisory board on our compliant technology, medCrowd, structured in three
rounds of discussion. Ten haematologists country-wide could respond at their
own convenience, without the need to carve out time to attend a specific time
and place.
Our client was also able to explore appropriate topics as and when the need arose, throughout the course of the activity. We provided end-to-end support from onboarding experts to the technology, managing the advisory board with full adverse event and signatory support.
On a quarterly basis, we provided
executive scientific reports with actionable insights. These were shared in an
easily disseminated format that our client could readily present to wider teams.
The benefit
Our client was able to use the insights gained from top experts
in the field, with a >90% response rate, to ensure they could paint a legitimate
and accurate picture of gene therapy as a new treatment for haemophilia to move
forward with their brand strategy.